Cumberland Pharmaceuticals (CPIX) Cash from Financing Activities (2010 - 2026)

Cumberland Pharmaceuticals has disclosed Cash from Financing Activities across 17 years of filings, most recently posting -$763300.0 for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$763300.0, up 86.19% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.0 million (up 74.42% YoY), and the FY2025 annual result was -$6.7 million, down 3525.79% from the prior year.
• Cash from Financing Activities came in at -$763300.0 for Q1 2026 at Cumberland Pharmaceuticals, down from -$681738.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $3.9 million in Q1 2022 to a low of -$5.5 million in Q1 2025.
• The 5-year median for Cash from Financing Activities is -$882596.0 (2023), against an average of -$988127.6.
• Peak annual rise in Cash from Financing Activities reached 401.86% in 2022, while the deepest fall reached 619.86% in 2022.
• Cumberland Pharmaceuticals' Cash from Financing Activities stood at -$2.8 million in 2022, then jumped by 46.52% to -$1.5 million in 2023, then gained by 7.31% to -$1.4 million in 2024, then surged by 50.54% to -$681738.0 in 2025, then slipped by 11.96% to -$763300.0 in 2026.
• The last three Cash from Financing Activities figures came in at -$763300.0 (Q1 2026), -$681738.0 (Q4 2025), and -$386879.0 (Q3 2025), per Business Quant data.